Business, energy, technology, markets and global industry news from Business News Today

basal cell carcinoma

PharmaDeviceNews basal cell carcinoma
Representative image: A clinician applies a microneedle skin patch as Medicus Pharma $MDCX advances its SkinJect treatment into an FDA-cleared Phase 2b study for basal cell carcinomas in Gorlin syndrome.
Pharma & Biotech

FDA clears Medicus Pharma SkinJect registrational study in Gorlin syndrome

FDA clears Medicus Pharma’s Phase 2b SkinJect study in Gorlin syndrome with biopsy-confirmed endpoints and two-year follow-up.

Read More
Representative image: A clinician uses a handheld skin assessment device, reflecting DermaSensor’s CE Mark and the growing role of AI-assisted skin cancer triage in European primary care.
Pharma & Biotech

Could DermaSensor’s NHS study turn AI skin cancer tools into primary care infrastructure?

Find out how DermaSensor’s CE Mark and NHS study could reshape AI-assisted skin cancer assessment across European primary care.

Read More
Pharma & Biotech

What Medicus Pharma Ltd.’s SkinJect application signals for Hedgehog pathway-driven cancers

Discover how SkinJect’s orphan drug bid could reshape Hedgehog-driven cancer treatment. Read what it means for clinicians, regulators, and investors.

Read More
Pharma & Biotech

What Verrica Pharmaceuticals’ VP-315 data may reveal about the future of skin cancer immunotherapy

Read how Verrica Pharmaceuticals’ VP-315 data could reshape skin cancer immunotherapy and what clinicians and investors should watch next.

Read More